Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

GLP-1 drugs could reshape fashion and body culture

4

Sep 2026

GLP-1 drugs could reshape fashion and body culture

As GLP-1 medications change American bodies and attitudes about weight, a West Virginia University fashion expert says their influence could reach all the way from consumers' closets to designers' drawing boards and retailers' racks.

Gestational diabetes history linked to earlier development of type 2 diabetes

3

Sep 2026

Gestational diabetes history linked to earlier development of type 2 diabetes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows that, in women that develop type 2 diabetes (T2D), those who had gestational diabetes (GD) when pregnant are developing T2D on average almost 13 years earlier than those who did not.

What your gut microbes may have to do with how your brain ages

3

Sep 2026

What your gut microbes may have to do with how your brain ages

This review examines how diet-driven changes in the gut microbiota and microbial metabolites may influence cognitive aging through immune, metabolic, neural, endocrine, and barrier-related pathways. It highlights SCFAs, tryptophan-derived metabolites, and bile acids as key signaling mediators while emphasizing that much of the mechanistic evidence remains preclinical and human evidence is largely associative.

Too little or too much testosterone may matter for heart rhythm

2

Sep 2026

Too little or too much testosterone may matter for heart rhythm

A review of clinical trials, observational studies, genetic analyses, and mechanistic research suggests that atrial fibrillation risk may follow a U-shaped relationship with testosterone, increasing at both low and high levels. Evidence on testosterone replacement therapy remains mixed, with researchers calling for prospective studies to determine whether mid-physiological testosterone targets and treatment formulation influence AF risk.

Immigrants face longer ICU stays after stroke in Canada

2

Sep 2026

Immigrants face longer ICU stays after stroke in Canada

Among people who have a stroke in Canada, immigrants were admitted to the intensive care unit (ICU) at similar rates as long-term residents or people who were born in Canada, but they were more likely to have longer stays in the ICU, according to a study published September 2, 2026, in Neurology, the medical journal of the American Academy of Neurology.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.